Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

Inclusion Criteria:

• 2 months of age or older

• diagnosis of secondarily-infected traumatic lesion (SITL) or impetigo (bullous ornon-bullous)

• negative urine pregnancy test (females of childbearing potential)

• total skin infection rating scale (SIRS) score of at least 8, which must include apus/exudate score of at least 3

• subject or parent/legal guardian willing and able to comply with protocol

• written informed, dated consent, and written assent (if applicable)

Exclusion Criteria:

• previous hypersensitivity to pleuromutilins or oxazolidinones

• phenylketonuria or known hypersensitivity to aspartame

• secondarily-infected animal/human bite, or puncture wound

• abscess

• chronic ulcerative lesion

• underlying skin disease (eg, eczematous dermatitis) with secondary infection

• systemic signs and symptoms of infection

• skin infection not appropriate for treatment by a topical antibiotic (eg, extensivecellulitis, furunculosis)

• subject requires surgical intervention for infection prior to study or likely willduring the study

• receipt of systemic antibacterial or steroid, or application of any topicaltherapeutic agent directly to wound within 24 hours of entry into the study

• subject currently receiving adrenergic agents

• subject currently receiving serotonergic agents

• history of pseudomembranous colitis

• known, pre-existing myelosuppression, history of myelosuppression with linezolid use,or receiving a medication that produces bone marrow suppression

• history of siezures

• history of severe renal failure and undergoing dialysis

• serious underlying disease that could be imminently life-threatening

• pregnant, breast feeding or planning a pregnancy, or not using accepted method ofcontraception (females of childbearing potential or <1 year post-menopausal)

• use of another investigational drug within 30 days prior to entry into this study

• previously enrolled in this study

• fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltaseinsufficiency (for subjects <12 years of age receiving linezolid suspension)